We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
INSP's Inspire V rollout has surpassed 75% of implanting centers as training and contracting near completion.
INSP stands to benefit from favorable reimbursement changes, with physician fee increase in 2026.
INSP faces short-term headwinds from GLP-1 trialing delays and higher operating expenses.
Inspire Medical Systems (INSP - Free Report) appears positioned for solid growth over the next few quarters as it navigates a significant product transition. Management highlighted strong clinical traction for Inspire V, clearer reimbursement pathways, and tight cost discipline, while also flagging short-term pressures from inventory conversion, evolving GLP-1 usage and heightened competitive and operational challenges.
Shares of this Zacks Rank #3 (Hold) company have lost 23.1% over the past six months compared with the industry’s 16.2% decline. The S&P 500 Index has increased 10.5% in the same time frame.
Inspire Medical, a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, has a market capitalization of $2.74 billion. The company projects 39.1% earnings decline for the fourth quarter of 2025. However, earnings are expected to return to growth in 2026.
Image Source: Zacks Investment Research
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 164.19%.
Positive Factors Driving Prospects
Expanding Patient Funnel and Disciplined Execution: Management noted that rising GLP-1 adoption is driving more patients into sleep clinics, effectively broadening the funnel for Inspire Medical rather than cannibalizing demand. Sleep specialists are increasingly treating GLP-1 patients in parallel with CPAP, which can later translate into Inspire referrals as adherence issues arise or patients qualify under BMI criteria.
At the same time, Inspire Medical showed solid operational execution, posting earnings outperformance through margin improvement and disciplined expense management even with elevated marketing investment. Healthy cash flow, ongoing share buybacks, and more focused territory oversight further support the company’s ability to scale efficiently as procedure volumes rebound.
Strong Inspire V Clinical Performance and Adoption Momentum: The Inspire V launch is emerging as a structural growth driver. Management cited compelling clinical data, including reduced surgical times, high nightly usage and strong synchronization with patient breathing, reinforcing superior outcomes versus prior generations. With physician training nearing completion and contracting more than 90%, the adoption of Inspire V has accelerated, reaching more than 75% of implanting centers. Importantly, early evidence shows higher utilization and efficiency at converted centers, with surgeons able to perform more implants per day. This combination of better outcomes, easier implantation, and higher throughput underpins sustained volume growth.
Favorable Reimbursement Outlook Supports Economics: Reimbursement dynamics are turning increasingly favorable. CMS has finalized an 11% increase to the physician fee schedule for CPT 64568 starting January 2026, and proposed hikes to hospital outpatient and ASC reimbursement rates would further enhance site-of-care economics. Coverage already exceeds 90% of insured lives, including Medicare beneficiaries.
Collectively, these developments should help close longstanding reimbursement gaps around Inspire systems, easing adoption for hospitals. Greater reimbursement clarity enhances the value proposition of Inspire V, improves profitability at the center level, and is likely to support faster conversion and higher utilization over time.
Key Challenges
GLP-1 Trialing and Timing Uncertainty: Although management views GLP-1 therapies as complementary over the long term, near-term trialing introduces uncertainty around procedure timing. Patients may delay surgical intervention while attempting pharmacologic weight loss, potentially dampening short-term volume growth. Management’s early-2026 growth outlook reflects prudence around this dynamic. While increased clinic visits and eventual CPAP noncompliance could ultimately benefit Inspire Medical, the pace at which GLP-1 patients convert to hypoglossal nerve stimulation remains difficult to predict, creating variability in near-term demand visibility.
Margin Pressure From Elevated OpEx and Competition: Despite robust gross margins, operating leverage is still limited by higher operating expenses, led by patient marketing and launch-related spending. Operating costs continue to grow faster than revenues on a year-over-year basis, and one-time items also pressured reported profitability. Management also pointed to early signs of competitive activity, though still modest, along with ongoing pricing and site-of-care dynamics at select centers.
Going forward, maintaining margin expansion will hinge on striking the right balance between continued investment in growth and incremental efficiency improvements, particularly as revenue growth settles into a low double-digit range.
Estimate Trend
Inspire Medical is witnessing a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings is pegged at $1.60 per share.
The Zacks Consensus Estimate for fourth-quarter 2025 revenues and loss per share is pegged at $269 million and 70 cents, respectively.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Key Takeaways
Inspire Medical Systems (INSP - Free Report) appears positioned for solid growth over the next few quarters as it navigates a significant product transition. Management highlighted strong clinical traction for Inspire V, clearer reimbursement pathways, and tight cost discipline, while also flagging short-term pressures from inventory conversion, evolving GLP-1 usage and heightened competitive and operational challenges.
Shares of this Zacks Rank #3 (Hold) company have lost 23.1% over the past six months compared with the industry’s 16.2% decline. The S&P 500 Index has increased 10.5% in the same time frame.
Inspire Medical, a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, has a market capitalization of $2.74 billion. The company projects 39.1% earnings decline for the fourth quarter of 2025. However, earnings are expected to return to growth in 2026.
Image Source: Zacks Investment Research
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 164.19%.
Positive Factors Driving Prospects
Expanding Patient Funnel and Disciplined Execution: Management noted that rising GLP-1 adoption is driving more patients into sleep clinics, effectively broadening the funnel for Inspire Medical rather than cannibalizing demand. Sleep specialists are increasingly treating GLP-1 patients in parallel with CPAP, which can later translate into Inspire referrals as adherence issues arise or patients qualify under BMI criteria.
At the same time, Inspire Medical showed solid operational execution, posting earnings outperformance through margin improvement and disciplined expense management even with elevated marketing investment. Healthy cash flow, ongoing share buybacks, and more focused territory oversight further support the company’s ability to scale efficiently as procedure volumes rebound.
Strong Inspire V Clinical Performance and Adoption Momentum: The Inspire V launch is emerging as a structural growth driver. Management cited compelling clinical data, including reduced surgical times, high nightly usage and strong synchronization with patient breathing, reinforcing superior outcomes versus prior generations. With physician training nearing completion and contracting more than 90%, the adoption of Inspire V has accelerated, reaching more than 75% of implanting centers. Importantly, early evidence shows higher utilization and efficiency at converted centers, with surgeons able to perform more implants per day. This combination of better outcomes, easier implantation, and higher throughput underpins sustained volume growth.
Favorable Reimbursement Outlook Supports Economics: Reimbursement dynamics are turning increasingly favorable. CMS has finalized an 11% increase to the physician fee schedule for CPT 64568 starting January 2026, and proposed hikes to hospital outpatient and ASC reimbursement rates would further enhance site-of-care economics. Coverage already exceeds 90% of insured lives, including Medicare beneficiaries.
Collectively, these developments should help close longstanding reimbursement gaps around Inspire systems, easing adoption for hospitals. Greater reimbursement clarity enhances the value proposition of Inspire V, improves profitability at the center level, and is likely to support faster conversion and higher utilization over time.
Key Challenges
GLP-1 Trialing and Timing Uncertainty: Although management views GLP-1 therapies as complementary over the long term, near-term trialing introduces uncertainty around procedure timing. Patients may delay surgical intervention while attempting pharmacologic weight loss, potentially dampening short-term volume growth. Management’s early-2026 growth outlook reflects prudence around this dynamic. While increased clinic visits and eventual CPAP noncompliance could ultimately benefit Inspire Medical, the pace at which GLP-1 patients convert to hypoglossal nerve stimulation remains difficult to predict, creating variability in near-term demand visibility.
Margin Pressure From Elevated OpEx and Competition: Despite robust gross margins, operating leverage is still limited by higher operating expenses, led by patient marketing and launch-related spending. Operating costs continue to grow faster than revenues on a year-over-year basis, and one-time items also pressured reported profitability. Management also pointed to early signs of competitive activity, though still modest, along with ongoing pricing and site-of-care dynamics at select centers.
Going forward, maintaining margin expansion will hinge on striking the right balance between continued investment in growth and incremental efficiency improvements, particularly as revenue growth settles into a low double-digit range.
Estimate Trend
Inspire Medical is witnessing a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings is pegged at $1.60 per share.
The Zacks Consensus Estimate for fourth-quarter 2025 revenues and loss per share is pegged at $269 million and 70 cents, respectively.
Stocks to Consider
Some better-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Boston Scientific (BSX - Free Report) and STERIS (STE - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.